Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. - Wikidata - awgldk - TriplyDB

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.

http://www.wikidata.org/entity/Q34257256

about

Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies Eph receptors as therapeutic targets in glioblastoma Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies.Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells.Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients.Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.Therapeutic targeting of EPH receptors and their ligands.Eph receptors and ephrins: therapeutic opportunities.The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells.Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.EphA2 Receptor Signaling Mediates Inflammatory Responses in Lipopolysaccharide-Induced Lung Injury Design considerations for dose-expansion cohorts in phase I trials Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers.

P2860

Q26830923-8CBBDAAC-6EEF-4FFB-90F5-CABFE2C28057 Q27000196-133D4EB3-18D7-4060-9CB4-C0EAB1239454 Q28077999-FB71BAC8-BB97-4206-B761-EBA7FE9C51D2 Q30605298-7787CEC2-71D9-4E5A-A8E6-20305F0DC05C Q33848124-4A4D40EB-87EA-45E9-8258-FDE25AE938C2 Q35666005-11A39D85-0E94-48C7-9E28-91FE3E3ACED1 Q35757569-6B705CF5-D464-4CF8-9EAE-FB1432426D0A Q35889278-4E1F317C-8667-4E97-98CB-2A700091CA7F Q36366709-665C9C9D-0EB9-434D-9905-A2B202FC8D1B Q37481237-5D4DAB19-7EB1-4ED5-B452-6D4371F89CDB Q38084826-9BDA87D4-11EE-4CF6-9A2B-ECC18F9A3764 Q38174793-311264C1-2774-4BC0-9397-6B9692BA8BF4 Q38257853-EE9507D4-1D9D-4D9E-AC34-3E3F93E5E2D5 Q38267385-518A08AE-26B0-471F-B583-8133670F5366 Q38798481-B0CD5A97-B976-4F7F-9DAF-69AFB100ABB0 Q41114117-1618654C-7BB4-49D5-8FAC-5C117BE7C278 Q41895594-94E1050B-6D0F-42CC-8A9B-83933A856FF6 Q43096291-01511EFF-2143-4F55-B7E7-6D19872B1693 Q51749008-678CE90D-E997-4111-8BD3-19E1C4B5AD0C Q55286883-EE403F8C-9A59-469C-9CA6-9275B4CC0C76

P2860

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.

http://www.wikidata.org/entity/Q34257256

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase 1, open-label study of M ...... ed or refractory solid tumors.

@ast

Phase 1, open-label study of M ...... ed or refractory solid tumors.

@en

Phase 1, open-label study of M ...... ed or refractory solid tumors.

@nl

type

label

Phase 1, open-label study of M ...... ed or refractory solid tumors.

@ast

Phase 1, open-label study of M ...... ed or refractory solid tumors.

@en

Phase 1, open-label study of M ...... ed or refractory solid tumors.

@nl

prefLabel

Phase 1, open-label study of M ...... ed or refractory solid tumors.

@ast

Phase 1, open-label study of M ...... ed or refractory solid tumors.

@en

Phase 1, open-label study of M ...... ed or refractory solid tumors.

@nl

P1433

Q34257256-C89EE21F-B96D-42B2-B876-A96307736C48

P1476

Q34257256-54578A0C-25F7-4730-BA49-E174A4100831

P2093

Q34257256-2CC5024F-DF01-4C23-9505-F74F8F1BB79D

Q34257256-2D396221-63B4-4AA4-BFE0-EA95053EC6BF

Q34257256-54C2593F-9ADA-4B82-B025-045DD3DE0F2E

Q34257256-5CDD5A64-464A-42D7-895C-B1164F302E47

Q34257256-6545B541-D56B-4D41-9685-45FC63B6D7FF

Q34257256-6CE5769F-1131-410A-8C71-CE80C7269038

Q34257256-91A9DB4C-0BE7-41B1-905E-769556DCB059

Q34257256-BF5603C4-F783-4BF8-8191-E049A5E0E4B7

P2860

Q34257256-0861AA44-EAF7-4FE2-A185-9E900BD79ACB

Q34257256-23E49BAE-F65B-44C1-81F6-A654956004B9

Q34257256-2B3205BB-93AF-4C74-8D6B-186060366163

Q34257256-3351CCE4-8A9B-4587-938C-99EC55238311

Q34257256-3724CACD-61C2-4F4F-AB1D-248B2133A4CF

Q34257256-3810CB30-789B-4B97-AB79-F4B84A2A5155

Q34257256-407114D3-6875-47B5-A566-79EDF8A7683D

Q34257256-4BFABE5A-9BE5-44F4-9F88-8429315AC2DF

Q34257256-4CEFEA27-A40C-4724-9E05-D4A8DEED8991

Q34257256-5F25F6EA-E7A6-4FDD-9E86-82D433DD063D

P2888

Q34257256-A2989082-B81E-43A0-BBE7-0DF5758571DB

P304

Q34257256-6F53E2BA-3C72-4A37-AE62-AF088FBA48C9

P31

Q34257256-22E101A1-4EA2-40DB-BC15-D9FE988CB6B3

P356

Q34257256-3835A9D2-BBFF-4A33-A261-6EFF9B592A2C

P433

Q34257256-292D7C8D-3463-44A7-8186-CEA1F667B182

P478

Q34257256-5B131C0D-1D7E-493C-9324-4935B8F90BA7

P577

Q34257256-52E80E87-193C-4564-86E5-297BE15DF193

P5875

Q34257256-3CA498D5-9E23-47C5-9827-826F6580C6A2

P6179

Q34257256-2F81A1F9-D59D-48DF-87A9-6DC1519C7321

P698

Q34257256-1FDA79D5-0803-47DD-9D22-E55409BC2BD1

P932

Q34257256-A3A3FFF4-051C-448D-BA9E-74DD94717642

P356

S10637-012-9801-2

P1433

Investigational New Drugs

P1476

Phase 1, open-label study of M ...... ed or refractory solid tumors.

@en

P2093

Christina M Annunziata

http://www.w3.org/2001/XMLSchema#string

Elise C Kohn

http://www.w3.org/2001/XMLSchema#string

Gabriel Robbie

http://www.w3.org/2001/XMLSchema#string

Manuela Buzoianu

http://www.w3.org/2001/XMLSchema#string

Nicole D Houston

http://www.w3.org/2001/XMLSchema#string

Patricia LoRusso

http://www.w3.org/2001/XMLSchema#string

Robert L Coleman

http://www.w3.org/2001/XMLSchema#string

Robert Lechleider

http://www.w3.org/2001/XMLSchema#string

P2860

cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases

Differential regulation of EphA2 in normal and malignant cells

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma.

The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Emerging strategies for EphA2 receptor targeting for cancer therapeutics.

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.

EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.

EphA2 as a target for ovarian cancer therapy.

P2888

s10637-012-9801-2

P304

77-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-012-9801-2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221867151

http://www.w3.org/2001/XMLSchema#string

P6179

1007747281

http://www.w3.org/2001/XMLSchema#string

P698

22370972

http://www.w3.org/2001/XMLSchema#string

P932

3553417

http://www.w3.org/2001/XMLSchema#string